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SUMMARY. There are several established risk factors for
intrahepatic cholangiocarcinoma (ICC), namely primary
sclerosing cholangitis, ﬁbropolycystic liver disease, parasitic
infection, intrahepatic biliary stones and chemical carcino-
gen exposure. However, the majority of patients with ICC do
not have any of these risk factors. Therefore, identiﬁcation of
other risk factors is warranted for the prevention and early
detection of ICC. We evaluated the risk factors for ICC in a
large-scale cohort study in the province of Osaka, Japan. This
retrospective cohort study included 154,814 apparently
healthy individual blood donors, aged 40–64 years at the
time of blood donation in the period 1991–1993. The aver-
age observation period was 7.6 years, resulting in 1.25
million person-years of observation. Incident ICC cases were
identiﬁed by linking the blood-donor database to the records
in the population-based cancer registry for the province.
There were 11 incident ICC cases during follow-up, with an
incidence rate of 0.88 per 100 000 person-years. Compared
with subjects aged 40–49 years, the subjects aged
50–54 years and 55–59 years had a signiﬁcantly higher risk
for ICC (hazard ratio [HR] = 5.90; 95%CI:1.08–32.31 and
11.07; 95%CI:1.98–61.79, respectively). Compared with
those with ALT level of 19 Karmen Units (KU) or less, subjects
with ALT level of 40 KU or higher had a signiﬁcantly higher
risk for ICC (HR: 8.30; 95%CI:1.47–46.83). Compared with
those who tested negative for both HBsAg and anti-HCV,
those who tested HBsAg-positive had a signiﬁcantly higher
risk for ICC (HR: 8.56; 95%CI: 1.33–55.20). Our results
suggest that HBV infection and liver inﬂammation are inde-
pendently associated with ICC development. These ﬁndings
need to be veriﬁed by further large cohort studies.
Keywords: aetiology, cholangiocarcinoma, cohort studies,
hepatitis, inﬂammation, liver.
INTRODUCTION
Intrahepatic cholangiocarcinoma (ICC) is the second most
common primary liver cancer, accounting for approximately
10–20% of liver cancers [1]. Worldwide, it is estimated to
account for 3% of all gastrointestinal cancers [2]. Advanced
ICC has a very poor prognosis with a median survival of less
than 24 months [3]. There is extensive variation among the
incidence rates of ICC in different parts of the world, and the
incidence is reported to be higher in East Asia [1]. The
reported incidence of ICC in several developed countries has
been increasing in recent years [1,4,5].
There are several established risk factors for ICC [1,4],
namely primary sclerosing cholangitis, ﬁbropolycystic liver
disease, parasitic infection, intrahepatic biliary stones and
chemical carcinogen exposure, but the majority of patients
with ICC do not have any of these risk factors. Therefore,
identiﬁcation of other risk factors is warranted for the pre-
vention and early detection of ICC. In addition to the
established risk factors mentioned earlier, some other
potential risk factors for ICC have been suggested, such as
infection with hepatitis B virus (HBV) [6–9], hepatitis C virus
(HCV) [9–14] or liver cirrhosis [7,11,12]. Almost all of the
studies that suggested these potential risk factors, however,
were case–control studies. Also, half of the reported studies
were conducted in the USA or Italy, and their results may
not be applicable for populations in other countries or areas,
partly because the relative importance of risk factors may
vary by country or by area. To our knowledge, no cohort
study has been reported from a non-Western country on the
risk factors for ICC. In this background, we conducted a
retrospective cohort study in Japan, using a large group of
Abbreviations: HBsAg, Hepatitis B surface antigen; HBV, hepatitis B
virus; HCV, hepatitis C virus; anti-HCV, antibody to HCV; HR,
hazard ratio; HTLV-1, human T-cell lymphotropic virus type 1; ICC,
intrahepatic cholangiocarcinoma; KU, Karmen Unit; OCR, Osaka
Cancer Registry.
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risk factors for ICC.
MATERIALS AND METHODS
Subjects
The subjects were those who were involved in our previous
study on the risk of developing hepatocellular carcinoma,
which was reported elsewhere [15]. They were selected from
voluntary blood donors who gave 1 235 926 allogeneic
blood donations at the Osaka Red Cross Blood Center between
1991 and 1993. The blood centre is in charge of managing
volunteer blood donations in the province of Osaka, which
had a population of approximately 8.6 million during this
period. Conditions required for potential blood donors in
Japan during the study period were described elsewhere [16].
In brief, they had to be aged between 16 and 64 years and
have a haemoglobin level of 12 g/dL or higher. Potential
blood donors were preliminarily screened by a self-adminis-
tered questionnaire with items regarding past and present
illnesses, history of blood transfusion, illegal drug use and
high-risk sexual behaviours. Major exclusion criteria in the
preliminary screening included: (i) known or potential infec-
tionwithHBV,HCV,humanimmunodeﬁciencyvirus(HIV)or
human T-cell lymphotropic virus type 1 (HTLV-1); (ii) pres-
ence or history of chronic liver disorders as well as malignant,
allergic or autoimmune disorders; (iii) history of illegal drug
use or high-risk sexual behaviour. Those who did not meet
any of the exclusion criteria in the preliminary screening
donated blood without monetary incentive. The donated
blood of these donors was tested for the earlier-described
viruses,and,iftestedpositive,thebloodwasdiscarded,butthe
information on the positive-tested donors was kept in the
blood-donordatabaseaswastheinformationonthenegative-
tested donors. Using this database containing information on
all ofthe donors andthe results ofthe serologicscreening test,
we identiﬁed 667 461 individual donors by donor birthdate,
sex, ﬁrst name, family name and ABO blood type. From these
individuals, we selected residents in Osaka province, aged
40 years or older at the time of blood donation, who were
negative for antibodies to HIV and HTLV-1. Those who were
39 years or younger were excluded because the incidence of
ICC in this age-group in the Japanese population was negli-
gible. Those infected with HCV or HBV were ﬁrst-time blood
donors who claimed to be asymptomatic at the time of blood
donation. Those who were infected with both HBV and HCV
(25 subjects) were also excluded. As a result, we identiﬁed
154 814 persons to be included in this cohort study.
Blood screening tests
The serum alanine aminotransferase (ALT) level expressed in
Karmen Units (KU) and serum total cholesterol level (mg/dL)
were obtained from the database. The ALT value in KU tested
by the blood centre can be translated into a value in Inter-
national Units by multiplying with 1.5 [17]. An individual
was deﬁned as having HCV infection if the titre of anti-HCV in
a second-generation passive hemagglutination assay (PHA)
(Dainabot Co., Ltd, Tokyo, Japan) was 2
12 or higher, because
the positive predictive value for being HCV-RNA-positive
using this cut-off point in Japanese blood donors was guar-
anteed [18]. An individual was considered to have HBV
infection if he/she was positive for HBsAg in a reverse passive
hemagglutination assay (Japan Red Cross, Tokyo, Japan).
Follow-up
The subjects were followed-up by record linkage between the
blood-donor database and the database of the Osaka Cancer
Registry (OCR) [19]. The records in the two databases were
linked by the parameters of sex, date of birth, address and
the ﬁrst character of the family name in Chinese letters. The
OCR is a population-based cancer registry that covers all of
the population in Osaka province. The OCR registers all
incident cancer cases using reports from health care facilities
in the province as well as death certiﬁcate information
provided by the Osaka Provincial Government [19]. In the
OCR database, ICC cases were identiﬁed by the ICD-10 code
(C22.1). The diagnosis of ICC was based on histological
examination and/or combined clinical, radiological (echog-
raphy, computed tomography and endoscopic retrograde
cholangio-pancreatography) and laboratory ﬁndings. Sub-
jects who remained unaffected by ICC were censored at the
last date of follow-up, 31 December 2000, as were the
subjects in the previous study [15]. The study protocol was
approved by both the Ethical Committee of Osaka Medical
Center for Cancer and Cardiovascular Diseases, and the
Ethical Committee of the Osaka Red Cross Blood Center.
Statistical analyses
The number of person-years of observation of the subjects
was determined, and the incidence rate of ICC per 100 000
person-years was calculated by the strata of age-group, sex,
ALT level, cholesterol level and HBV/HCV infection status.
Ninety-ﬁve per cent conﬁdence interval (95%CI) for the rate
was calculated using Byars approximation of the exact
Poisson test. Independent factors associated with the devel-
opment of ICC were analysed by Cox proportional hazards
model, and hazard ratios were calculated with 95%CI. In the
model, age-group, sex, ALT level, cholesterol level, and HBV/
HCV infection were included as independent variables. Data
analyses were performed with the SAS/PC statistical package
(SAS Institute, Cary, NC, USA).
RESULTS
The baseline characteristics of the 154 814 study subjects
andincidenceratesofICCstratiﬁedbydifferentcharacteristics
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of 40 KU or higher, with positive HBsAg test, and with posi-
tive anti-HCV test were 2.2%, 1.6% and 1.2%, respectively.
The average observation period was 7.6 years, resulting in
12.50 · 10
5 person-years. There were 11 incident ICC cases,
with an incidence rate of 0.88 per 100 000 person-years
(95%CI: 0.44–1.58). By strata, the point-estimate incidence
rate was higher among those aged 55–59 years, those with
ALT level of 40 KU or higher, or those who tested positive for
HBsAg or anti-HCV.
Factors associated with the development of ICC in blood
donors are shown in Table 2. Compared with subjects aged
40–49 years, the subjects aged 50–54 years and
55–59 yearshadasigniﬁcantlyhigherriskforICC.Compared
with those with ALT level of 19 KU or lower, subjects with
ALTlevelof40 KUorhigherhadasigniﬁcantlyhigherriskfor
ICC. Compared with those who tested negative for both
HBsAg and anti-HCV, those who tested positive for HBsAg
had a signiﬁcantly higher risk for ICC. The hazard ratio for
anti-HCV positivity was 2.63, although it was not signiﬁcant.
The characteristics of the 11 ICC cases identiﬁed during the
follow-up period are summarized in Fig. 1. The observation
period from the date of blood donation to the date of diagnosis
of ICC ranged from 14 to 90 months among the eight cases
not infected with HBV or HCV, while it was 41, 77 and
108 months in the one HCV- and two HBV-infected cases.
DISCUSSION
To our knowledge, this is the ﬁrst cohort study that inves-
tigated the risk factors for ICC in East Asia, where the
incidence of primary liver cancer is high [20]. A literature
search in Medline from January 1992 up to May 2009
revealed that all of the analytical studies on the risk factors
for ICC in the past employed the case–control design, except
for one study (Table 3). The only cohort study in the past
was reported from the USA in early 2009 and focused on the
risk of HCV infection for ICC and other hepatobiliary carci-
nomas [10]. The present study assessed whether HBV
infection or liver inﬂammation as expressed by the ALT level
was independently associated with ICC, which was not
scrutinized in the cohort study from the USA.
We found that the incidence rate of ICC among the
apparently healthy population aged 40–64 years was
Table 1 Baseline characteristics of the study subjects of blood donors aged 40–64 years and incidence rates of intrahepatic
cholangiocarcinoma.
N (%)
ICC
incident
cases
Person-years
(·10
5)
Incidence rate
of ICC (per 10
5
person-years)
95% Conﬁdence interval*
of ICC incidence rate
(per 10
5 person-years)
All cases 154 814 100.0 11 12.50 0.88 0.44–1.58
Age at blood donation (years)
40–49 90 223 58.3 2 7.29 0.27 0.03–0.99
50–54 35 308 22.8 4 2.85 1.41 0.38–3.59
55–59 20 668 13.4 4 1.67 2.40 0.64–6.13
60–64 8615 5.6 1 0.69 1.44 0.02–8.06
Sex
Male 84 205 54.4 7 6.81 1.03 0.41–2.12
Female 70 609 45.6 4 5.68 0.70 0.19–1.80
ALT (KU)
19 or lower 127 757 82.5 7 10.32 0.68 0.27–1.40
20–39 23 666 15.3 2 1.91 1.05 0.12–3.78
40 or over 3391 2.2 2 0.27 7.36 0.83–26.74
Cholesterol (mg/dL)
139 or lower 4533 2.9 0 0.37 0.00 0.00–12.60
140–199 82 575 53.3 8 6.67 1.20 0.52–2.36
200 or over 67 706 43.7 3 5.46 0.55 0.11–1.61
Hepatitis B/C virus infection
HBsAg+ 2519 1.6 2 0.22 9.08 1.02–32.82
anti-HCV+ 1927 1.2 1 0.16 6.34 0.08–34.77
All negative 150 368 97.1 8 12.12 0.66 0.28–1.30
None of the subjects was positive for human immunodeﬁciency virus or human T-cell lymphotropic virus type 1. All negative:
tested negative for both anti-HCV and HBsAg. ALT, alanine aminotransferase; HBsAg+, tested positive for Hepatitis B surface
antigen and negative for Hepatitis C virus antibody; anti-HCV+, tested positive for anti Hepatitis C virus antibody and negative
for Hepatitis B surface antigen. *95% conﬁdence interval was calculated by Byars approximation of the exact Poisson test.
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the HCV carrier rate is relatively high [21]. This ﬁgure is
higher than the estimated incidence rate of 0.037 in the
population aged 40–69 years reported in another Japanese
study [22], of which the rate was underestimated because
the numerator was derived from a multi-centre survey of
primary liver cancer across Japan [23,24] with limited
population coverage. The point-estimate incidence rate of
ICC among anti-HCV positive subjects in our study (6.34 per
100 000 person years) was not very different from the
estimate in the cohort study from the USA (4.0 per 100 000
person years) [10], even though our conﬁdence interval was
quite large.
Our results suggest that HBV infection is likely to be an
independent risk factor for ICC in Japan. Studies in the past,
in aggregate, suggested that HBV and HCV infection are
potential risk factors for ICC, but their impact might be dif-
ferent across different countries or areas (Table 3). Several
studies from the USA and Italy [9–12,14] consistently found
that HCV infection was signiﬁcantly associated with ICC,
while the association with HBV infection was inconsistent or
not assessed. On the other hand, recent hospital-based case–
control studies from Korea and Shanghai, China [7,8] found
that not HCV but HBV infection was signiﬁcantly associated
with ICC. The most recent study from Taiwan found that
both HBV and HCV are signiﬁcantly associated with ICC [6].
To our knowledge, our study is the ﬁrst cohort study to
demonstrate a signiﬁcant association between HBV infection
and ICC. This higher level of evidence supports prior obser-
vations of the association in East Asia. Our ﬁnding is also
supported by the results of the earlier mentioned multi-cen-
tre primary liver cancer survey in Japan, which consistently
showed a high prevalence of HBsAg among ICC cases (4–9%)
since 1990 [24][detailed data since 1990 available in reports
by the The Japan Society of Hepatology (Japanese only)].
The mechanism of carcinogenesis by HBV in intrahepatic
bile ducts has not yet been elucidated, but HBV infection is
an established risk factor for hepatocellular carcinoma.
Because both hepatocytes and cholangiocytes differentiate
from the same progenitor cells, HBV might induce carcino-
genesis in both cell types through the same mechanism. The
HBV gene has been detected in cholangiocarcinoma tissue in
some studies [25,26], and its presence has been associated
with the potential of carcinogenesis in human cholangio-
cytes [27]. Alternatively, hepatitis-associated ICC may arise
from hepatic progenitor cells, as suggested by Lee et al. [6].
In our study, the association between ICC and HCV
infection was not signiﬁcant, even though its hazard ratio
Table 2 Factors associated with the
development of intrahepatic cholangio-
carcinoma in blood donors according to
Cox proportional hazard analysis
Variable n ICC Hazard ratio 95%CI
Age at blood donation (years)
40–49 90 223 2 1.00
50–54 35 308 4 5.90 1.08–32.31
55–59 20 668 4 11.07 1.98–61.79
60–64 8615 1 6.61 0.59–74.59
Sex
Male 84 205 7 1.00
Female 70 609 4 0.79 0.22–2.82
ALT level (KU) at blood donation
19 or lower 127 757 7 1.00
20–39 23 666 2 1.47 0.29–7.36
40 or over 3391 2 8.30 1.47–46.83
Cholesterol level at blood donation*
200 mg/dL or higher 67 706 3 1.00
140–199 82 575 8 2.36 0.60–9.26
139 or lower 4533 0 – –
Hepatitis B/C virus infection
All negative 150 368 8 1.00
HCV-Ab + 1927 1 2.63 0.25–27.73
HBs Ag+ 2519 2 8.56 1.33–55.20
None of the subjects was positive for human immunodeﬁciency virus or human
T-cell lymphotropic virus type 1. Age (4 categories), sex, serum ALT level at blood
donation(3categories),andserumcholesterollevelatblooddonation(3categories)
wereincludedasindependentvariablesintheCoxproportinalhazardanalysis.ALT,
alanine aminotransferase; Cl, conﬁdence interval; HBsAg+, tested positive for
Hepatitis B surface antigen and negative for Hepatitis C virus antibody; HCV-Ab+,
tested positive for anti Hepatiis C virus antibody and negative for Hepatitis B surface
antigen; ICC, intrahepatic cholangiocarcinoma; KU, Karmen Unit.
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association if our cohort had been even larger. In the multi-
centre survey in Japan, the prevalence of anti-HCV among
ICC cases (20–30%) has consistently been high since 1990
[24]. [detailed data since 1990 available in reports by The
Japan Society of Hepatology (Japanese only)].
Our ﬁndings also suggest that liver inﬂammation as
expressed by ALT level ‡40 KU may be an independent risk
factor for ICC after adjustment for HCV and HBV infection
status. In our previous study using the same cohort, we also
found that liver inﬂammation is an independent risk factor
for hepatocellular carcinoma [15]. The only study in the past
that assessed the impact of ALT level on the development of
ICC was performed in a case–control study [13], and found a
signiﬁcant association between ICC and ALT level of ‡40 IU,
independent of HBV or HCV infection status. In addition to
viral hepatitis, fatty liver disease is likely to be a major cause
of liver inﬂammation in the subject population. Here,
inﬂammation of hepatocytes may connote inﬂammation of
intrahepatic bile ducts. Epidemiologic and experimental
evidence shows that inﬂammation of the bile duct from
various aetiologies induces carcinogenesis in cholangiocytes
[1,4,28]. Alternatively, inﬂammation of hepatic progenitor
cells may result in cholangiocarcinoma [6].
Liver cirrhosis has been suggested as an independent risk
factor for ICC in some case–control studies where liver
inﬂammation was not included as a covariate [7,11,12]. We
were not able to assess the risk of liver cirrhosis for ICC
because of lack of this information in the blood-donor
database, but patients with known liver cirrhosis were
excluded in our study upon screening before blood donation,
minimizing the effect of a potential confounding factor. In
part, the presence of liver cirrhosis among ICC cases in the
case–control studies might be a proxy of present or past liver
inﬂammation. If so, ICC might be associated with liver
inﬂammation in cohort studies using subjects in a pre-
cirrhosis state, and with liver cirrhosis in case–control
studies. The only case–control study that included both liver
cirrhosis and inﬂammation as covariates demonstrated that
ICC was signiﬁcantly associated with the presence of
inﬂammation but not with liver cirrhosis [13]. Further
studies on this issue are necessary.
Our study has some potential limitations. First, informa-
tion on the presence of established major risk factors for ICC,
namely infection with liver ﬂuke, intrahepatic biliary stones,
ﬁbropolycystic liver disease and primary sclerosing cholan-
gitis, was not available in the blood-donor database, and we
were not able to adjust the hazard ratios for them. However,
liver ﬂuke (Clonorchis sinensis) infection was already rare in
Osaka and surrounding areas by the 1960s [29]. Also,
patients with chronic liver or autoimmune diseases were
excluded from blood donors upon their claim in the
screening questionnaire. Therefore, inﬂuence from known
confounding factors should be minimal in our study. Second,
the number of ICC cases in our study was fairly limited be-
cause of the relatively low incidence of ICC, resulting in a
wide conﬁdence interval in the estimated incidence rates or
relative risks. Our ﬁndings on the risk of viral infection and
inﬂammation, however, were consistent with observations
in past studies, and it should, at least in part, warrant the
validity of our ﬁndings. Third, we may have underestimated
the incidence rates of ICC in our study, because the number
of person-years of observation described in the Results sec-
tion was not adjusted by the number of subjects who might
have moved out of the province or died, before the ﬁnal date
of follow-up. The estimated incidence rates, after adjustment
using the revised values for these parameters, would be
approximately 25% higher than the ﬁgures described earlier.
Fig. 1 Characteristics of the 11 intrahepatic cholangiocarcinoma (ICC) cases identiﬁed among the cohort of blood donors
during the follow-up period.
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perfect, potentially reducing the estimated incidence of ICC.
Nevertheless, we assume that the coverage for cancers with
poor prognosis, like ICC, was sensitive enough because of the
use of death certiﬁcate information. Also, the imperfect
coverage of the registry should not affect the relative risk for
HBV/HCV infection or liver inﬂammation because the reg-
istry coverage was independent of the presence of these risk
factors.
In conclusion, our results suggest that HBV infection and
liver inﬂammation are independently associated with ICC
development. These ﬁndings as well as their association with
liver cirrhosis and other potential risk factors need to be
veriﬁed by further large cohort studies.
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Table 3 Results of analytical studies on the association of intrahepatic cholangiocarcinoma (ICC) and hepatits B and C virus
Authors
and year
Study
area Type of study
No. of
ICC case
RR (95% CI)
for HBV
infection*
RR (95% CI)
for HCV
infection*
Shin et al.
1996 [30]
Pusan,
Korea
Case–control,
hospital- based
41 OR = 1.3 (0.3–5.3) OR = 3.9 (0.9–17.1)
Donato et al.
2001 [14]
Italy Case–control,
hospital- based
26 OR = 2.7 (0.4–18.5) OR = 9.7 (1.6–58.9)
Yamamoto et al.
2004 [13]
Osaka,
Japan
Case–control,
hospital- based
50 OR = 1.8 (0.3–10.1) OR = 16.8 (5.7–50.0)
Shaib et al.
2005 [12]
TX, USA Case–control,
Medicare- beneﬁciaries
625 OR = 0.8 (0.1–5.9) OR = 6.1 (4.3–8.6)
Welzel et al.
2007 [11]
USA Case–control,
population-based
535 – OR = 5.4 (2.9–10.2)
Shaib et al.
2007 [9]
TX, USA Case–control,
hospital-based
83 OR = 28.6 (3.9–1268.1) OR = 7.9 (1.3–84.5)
Lee et al.
2008 [7]
Korea Case–control,
hospital-based
622 OR = 2.3 (1.6–3.3) OR = 1.0 (0.5–1.9)
Zhou et al.
2008 [8]
Shanghai,
China
Case–control,
hospital-based
312 OR = 8.8 (5.9–13.1) OR = 0.9 (0.3–3.1)
Lee et al.
2009 [6]
Taiwan Case–control,
hospital-based
160 OR = 5.0 (2.8–9.0) OR = 2.7 (1.2–6.3)
El-Serag et al.
2009 [10]
USA Cohort, veterans
population
37 – HR = 2.6 (1.3–5.0)
Tanaka et al.
(present)
Osaka, Japan Cohort, blood
donor population
11 HR = 8.6 (1.3–55.2) HR = 2.6 (0.3–27.7)
Note: Hepatitis B virus infection status was identiﬁed by the presence of HBs antigen except the study by Shaib et al. 2007. ()):
not asssessed as a covariate. Cl, conﬁdence interval; HBV, hepatitis B virus; HCV, hepatitis C virus; RR, relative risk of develping
intrahepatic cholangiocarcinoma; OR, adjusted odds ratio by multiple logistic regression analysis; HR, adjusted hazard ratio by
Cox proportional hazard regression analysis. *The original ﬁgures reported in each study were rounded up to the ﬁrst decimal
place.
HBV infection status veriﬁed by the antiHBc+ and HBsAg); Odds ratio for HBsAg+/antiHBc) was shown to be 2.9
(95%CI: 0.1–236.9).
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Intrahepatic cholangiocarcinoma and hepatitis virus 747and Welfare, and by a Grant-in-Aid for Scientiﬁc Research
(B) from the Japanese Ministry of Education, Culture, Sports,
Science, and Technology.
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